Form 4: Atara Biotherapeutics CAO Executes Tax-Related Stock Sale

Chief Accounting Officer Yanina Grant-Huerta sold 2,414 shares of Atara Biotherapeutics to cover tax obligations.

Summary

• Yanina Grant-Huerta, Chief Accounting Officer of Atara Biotherapeutics, Inc., sold 2,414 shares of common stock.
• The transaction occurred on May 18, 2026, at a weighted average price of $9.1286 per share.
• The sale was executed automatically to satisfy tax withholding obligations related to the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and mandatory to satisfy tax obligations.

Positives

• The sale was a mandatory 'sell-to-cover' transaction rather than a discretionary divestment, indicating no change in management sentiment regarding the company's future.

Negatives

• The transaction resulted in a reduction of the reporting person's direct beneficial ownership to 49,636 shares.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard industry practice for executives to manage tax liabilities upon the vesting of equity compensation and do not typically signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation tax management in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was non-discretionary.

Key Dates

Keywords

Atara Biotherapeutics, ATRA, Insider Trading, Form 4, Biotech, Tax Withholding